Our INDx indication extension platform provides you with new commercial opportunities to reposition your patented drugs and candidates in novel indications with significant revenue potential and patient benefits.
We use our unique high-resolution patient stratification insights across over 30 disease areas to systematically identify new opportunities for your assets to accelerate your entry into new markets at reduced risk and cost.
Analyze your current pipeline and in-licensing candidates to evaluate their indication extension potential.
What INDx provides you:
Your INDx Innovation Engine
Proprietary data repository containing novel insights from >30 disease studies + 2 new indications added every month
CASE STUDY: INDICATION EXTENSIONS
A mid-sized pharmaceutical company wanted to maximize the value of its patented assets by identifying new commercial opportunities for its approved drugs and candidates.
PrecisionLife performed a systematic analysis of the company’s pipeline and on-market assets, mapping to our unique disease insights in DiseaseBank™. We then evaluated each opportunity to prioritize those with the highest market value and easiest route to approval.
Our analysis identified 6 priority opportunities to extend into high-value indications within key therapeutic areas. The opportunities were in late-stage trials with an already established safety profile and a third of the opportunities were for drugs already approved and on-market.
Each opportunity included patient stratification biomarkers and high efficacy prediction scores to minimize the risk of expensive trial failures due to efficacy and enable effective new treatments to get to market quicker for the benefit of patients.
